Design of $AZN Volga is pretty similar to $MRK KN-905, apart from inclusion of an Imjudo cohort. Why does adding Imjudo into the mix make things apparently worse? Tox? https://t.co/Nrc32lZcso
$AZN Volga might have matched $MRK $PFE KN-905 in cis-ineligible patients, but here comes chemo-free Padcev + Keytruda in the cis-eligible setting. Via @ApexOnco -> https://t.co/KmwCfgZLBm
Possible reason, on further thought: $AZN Serena-6 proposed giving treatment sooner than standard; $RHHBY Imvigor-011 proposes to eliminate it in patients who might not need it.
Why no #odac for $RHHBY Imvigor-011? Pdufa date May 2026, uses ctDNA to guide treatment decision in a similar way to $AZN Serena-6 study of camizestrant - which did get an odac.
Just to rub salt into $AZN's wounds then. $ARVN https://t.co/kivCygY5ZL
@ablT315I @AppleHelix Oh, did you notice this gem from Joshua Donaldson (FDA reviewer): "The applicant $AZN cancelled the teleconferences associated with each of these meeting requests." https://t.co/oStDKxXQdV
@AppleHelix Agreed, and I though Capitello-281 was on far shakier ground than Serena-6. FDA basically told $AZN: if you don't show a strong PFS benefit you need OS. Result: weak PSF, no OS benefit. And yet, Truqap gets the thumbs up. What do I know!
OS curves in Truqap Capitello-281 study in PTEN deficient mHSPC $AZN, per adcom https://t.co/nyWpzLQjpJ
Will the FDA approve $AZN camizestrant despite the 6-3 vote adcom against Serena-6?
Yet again I'm wrong on an adcom outcome! So I guess Truqap now sails through unopposed $AZN https://t.co/Ci3f1Qfqk9
$AZN Serena-6 immature OS curves as revealed at the adcom. Not sure we've seen these before. https://t.co/L9oAQxhrh9
@AppleHelix Case against camizetrant seems pretty thin so far $AZN
$AZN refutes FDA's cardiac tox claim https://t.co/bCnd1bRbtL
$AZN camizestrant voting question for the odac: https://t.co/YArq80g3f1
The FDA review team's case against $AZN camizestrant:
ESR1 detection isn’t established
No info on long-term benefits
No OS benefit (might never see one)
PFS2 endpoint is BS
Calls out cardiac tox https://t.co/RwItZVpGU2
$AZN adcom starting now.
Background on $AZN Serena-6, via @ByMadeleineA -> https://t.co/YNYQ697rlf
And on Capitello-281 -> https://t.co/ucskHwSgkC
Reminder that the dual $AZN ODAC takes place tomorrow. Camizestrant Serena-6 trial being debated in the morning, then Truqap Capitello-281 in the afternoon. Youtube link -> https://t.co/RDcvhRqVWR
Actually, Avanzar slip from H1 -> H2 2026 was already disclosed by $DSNKY in Feb. The other two delays are new though $AZN
Looks like $ERAS was taking lessons from $AZN $DSNKY https://t.co/ukxzGGCdas
Now Avanzar readout slips from H1 to H2 2026. Plus further delays for Tropion-Lung07 & 08 $AZN https://t.co/iW8zSQw8Uv
...and here comes another $AZN "Titan" project, AZD8359 - Astra's 5th (!) against Steap2 #AACR26 https://t.co/CN4CXTzmr6 https://t.co/u2YfJ9W8xA
Fun to see $LLY snatch $AZN's double-Asco plenary crown at #Asco26
Kelonia turns #ASH25 late-breaker into buyout, with $LLY's second move into in vivo Car-T. Via @ApexOnco -> https://t.co/NPhdnuhPu3 $AZN $GILD
$LLY Kelonia tech is based on a modified, inactivated lentivector, so similar to $GILD Interius, $ABBV Umoja & $AZN Esobiotec. $ABBV Capstan uses lipid nanoparticle mRNA. https://t.co/omoGt4MvaM
Just disclosed in #AACR26 abstracts: $AZN AZD4956 = DNA pol theta inhibitor. My story from when it entered phase 1/2 Parthenon study +/-saruparib -> https://t.co/bHoOKqd7da
We know $ARVN is no different, and I doubt $OLMA will be. You can game a trial, but you can't really circumvent basic science $AZN $RHHBY $LLY
$AZN isn't the only company that still believes in PD-(L)1 x TIGIT: SH006 just went into phase 3!
https://t.co/AxyTJdFBzF
And here's what $AZN has in store for AZD0120, via @ApexOnco -> https://t.co/xE9uzw5RFp
The enlarged $TPST prioritising a CD19 x BCMA Car-T (TPST-2003), just as $AZN launches its phase 3 study of (ex $GRCL) AZD0120/GC012F: https://t.co/o5QBIUWIS7
So $LLY not interested in oncology applications of Orna's in vivo Car-T? $ABBV $AZN $BMY $GILD https://t.co/wB3rR5LID8
Confirmned discontinuation of $NVS PIT565, which seems to be a specifically targeted T-cell engager (also hit CD2). cf $AZN Titan platform.
CT-gov quietly discloses that $AZN put Datroway into Tropion-Lung17 last Oct. Basically a do-over of Tropion-Lung01, but in non-squam and in TROP2 +ve only (using QCS assay?) https://t.co/cp2di8dcVf $DSNKY $MRK $GILD
...while ATR inhibition fails again. No surprise there TBH https://t.co/LNra4muDj0 $AZN $RPTX $MKGAF $RHHBY
$AZN follows $LLY $PFE $AMGN $ONC & $ALPMF into pan-KRAS, but should it be looking more to pan-RAS approaches like $RVMD & $ERAS? Via @ApexOnco -> https://t.co/MioOWziuSt
@NotGenentech @bioinvestor24 Here's a list of just the clinical pan-RAS & pan-KRAS assets from Oncologypipeline $RVMD $LLY $ONC $RHHBY $PFE $ERAS $AZN $AMGN $ALPMF https://t.co/oeb4Yr2nzo
JAB-23425, which appears to have been an earlier molecule in Jacobio's pan-KRAS series, but presumably closely related to $AZN JAB-23E73. Poster from #AACR23 https://t.co/VZytnlTpiV
$AZN just paid Jacobio $100m for ex-China rights to the pan-KRAS inhibitor JAB-23E73 https://t.co/NyCItnvJ0h
...in case you didn't read to the end, $AZN $DSNKY Tropion-Lung15 study of Datroway has also been halted, also because of ILD (though no deaths cited specifically in this case).
Pivotal ifinatamab deruxtecan trial on global clinical halt over ILD deaths. Scoop via @ApexOnco -> https://t.co/XNvk4BD4Sd $MRK $DSNKY $AZN
@NotGenentech @jq1234t $AZN will 100% succeed with Fc-reduced MAb.
Shock! $LLY reveals Inluriyo + Verzenio combo filing in ESR1m only, despite showing #SABCS25 promise in ESR1w/t. Scoop via @ApexOnco -> https://t.co/gUDeeMpmXb $RHHBY $AZN $ARVN $OLMA
Say hello to $AZN, last man standing in #tigit, and holder of an unconfortable similarity to $RCUS $GILD. Via @ApexOnco -> https://t.co/mqqRC9NaGZ
So where does this the #tigit Fc debate?
Fc-active: $GSK $ITOS fail, $MRK fail, $RHHBY fail
Fc-silent: $RCUS $GILD fail
Fc-reduced: $AZN $CGEN ?
@avidresearch Wait until you see $AZN CD8-based T-cell engagers! (Perhaps.)
$LLY Jaypirca looks best... up to a point. Via @ApexOnco from #ASH25 https://t.co/SgHJrraNrI $ONC $AZN $JNJ $ABBV $NRIX
@herbert_ou Yes, but does this make it an $AZN project? Or does one of the investigators just happen to be affiliated with AZN? I'd never heard of an AZN DLL3 Car-T, and the code is weird.
GC511B appears to be an $AZN Car-T therapy against DLL3. Can anyone corroborate? https://t.co/BsCiZ6UBmI https://t.co/5a6ebgFJXE
Is it a reverse merger? Is it a fund raising? I've tried to decipher the $TPST Factor deal, which is structured to avoid litigation vs $CLLS & $AZN. Via @ApexOnco -> https://t.co/C2XYWk7rtd
Akeso claims cadonilimab is safest in class as well as first in class PD-1 x CTLA-4. So dissing $AZN (notoriously toxic) volrustomig? #Jefferies25
